Emergent BioSolutions (EBS) Tops Q3 EPS by $1.27
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.23 +6.13%
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.37, $1.27 better than the analyst estimate of $0.10. Revenue for the quarter came in at $293.8 million versus the consensus estimate of $290.33 million.
GUIDANCE:
Emergent BioSolutions sees FY2024 revenue of $1.065-1.125 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning (GLW) files for up to $2B offering of common shares
- BetterLife Pharma files final prospectus for $100M public offering
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
